p.123 抽出テキスト

of the EAPCI. EuroIntervention 2020;16:e875–90. https://doi.org/10.4244/eij-d-20- 00487 1183. Taniwaki M, Windecker S, Zaugg S, Stefanini GG, Baumgartner S, Zanchin T, et al. The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J 2015;36:2167–76. https://doi.org/10.1093/eurheartj/ehv227 1184. Pereg D, Fefer P, Samuel M, Wolff R, Czarnecki A, Deb S, et al. Native coronary artery patency after coronary artery bypass surgery. JACC Cardiovasc Interv 2014;7: 761–7. https://doi.org/10.1016/j.jcin.2014.01.164 1185. Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, et al. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE consortium (prevention of late stent thrombosis by an interdisciplinary global European effort). Circulation 2017;136:1007–21. https://doi.org/10.1161/ circulationaha.117.026788 1186. Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am Coll Cardiol 2020;75:2664–78. https://doi.org/ 10.1016/j.jacc.2020.04.006 1187. Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J 2023; 44:1343–57. https://doi.org/10.1093/eurheartj/ehad026 1188. Elgendy IY, Mahmoud AN, Elgendy AY, Mojadidi MK, Elbadawi A, Eshtehardi P, et al. Drug-eluting balloons versus everolimus-eluting stents for in-stent restenosis: a meta-analysis of randomized trials. Cardiovasc Revasc Med 2019;20:612–8. https:// doi.org/10.1016/j.carrev.2018.08.010 1189. Doenst T, Sousa-Uva M. How to deal with nonsevere stenoses in coronary artery bypass grafting—a critical perspective on competitive flow and surgical precision. Curr Opin Cardiol 2022;37:468–73. https://doi.org/10.1097/hco.0000000000000993 1190. Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, et al. Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. J Am Coll Cardiol 2009;53:232–41. https://doi.org/10. 1016/j.jacc.2008.10.011 1191. Mehta RH, Ferguson TB, Lopes RD, Hafley GE, Mack MJ, Kouchoukos NT, et al. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. Circulation 2011;124:280–8. https://doi.org/10.1161/circulationaha.110.991299 1192. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 2002;40:1951–4. https://doi.org/10. 1016/s0735-1097(02)02560-3 1193. Xenogiannis I, Tajti P, Hall AB, Alaswad K, Rinfret S, Nicholson W, et al. Update on cardiac catheterization in patients with prior coronary artery bypass graft surgery. JACC Cardiovasc Interv 2019;12:1635–49. https://doi.org/10.1016/j.jcin.2019.04.051 1194. Doenst T, Haverich A, Serruys P, Bonow RO, Kappetein P, Falk V, et al. PCI and CABG for treating stable coronary artery disease: JACC review topic of the week. J Am Coll Cardiol 2019;73:964–76. https://doi.org/10.1016/j.jacc.2018.11.053 1195. Sabik JF 3rd, Raza S, Blackstone EH, Houghtaling PL, Lytle BW. Value of internal thoracic artery grafting to the left anterior descending coronary artery at coronary reoperation. J Am Coll Cardiol 2013;61:302–10. https://doi.org/10.1016/j.jacc.2012.09.045 1196. Brener SJ, Lytle BW, Casserly IP, Ellis SG, Topol EJ, Lauer MS. Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery. Eur Heart J 2006;27:413–8. https://doi.org/10. 1093/eurheartj/ehi646 1197. Brilakis ES, O’Donnell CI, Penny W, Armstrong EJ, Tsai T, Maddox TM, et al. Percutaneous coronary intervention in native coronary arteries versus bypass grafts in patients with prior coronary artery bypass graft surgery: insights from the Veterans Affairs clinical assessment, reporting, and tracking program. JACC Cardiovasc Interv 2016;9:884–93. https://doi.org/10.1016/j.jcin.2016.01.034 1198. Caceres J, Atal P, Arora R, Yee D. Enhanced external counterpulsation: a unique treatment for the “No-Option” refractory angina patient. J Clin Pharm Ther 2021; 46:295–303. https://doi.org/10.1111/jcpt.13330 1199. Verheye S, Jolicoeur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, et al. Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med 2015;372: 519–27. https://doi.org/10.1056/NEJMoa1402556 1200. Hochstadt A, Itach T, Merdler I, Ghantous E, Ziv-Baran T, Leshno M, et al. Effectiveness of coronary sinus reducer for treatment of refractory angina: a meta-analysis. Can J Cardiol 2022;38:376–83. https://doi.org/10.1016/j.cjca.2021.12. 009 1201. Foley MJ, Rajkumar CA, Ahmed-Jushuf F, Simader FA, Chotai S, Pathimagaraj RH, et al. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial. Lancet 2024;403: 1543–53. https://doi.org/10.1016/s0140-6736(24)00256-3 1202. Velagapudi P, Turagam M, Kolte D, Khera S, Hyder O, Gordon P, et al. Intramyocardial autologous CD34+ cell therapy for refractory angina: a meta-analysis of randomized controlled trials. Cardiovasc Revasc Med 2019;20:215–9. https://doi. org/10.1016/j.carrev.2018.05.018 1203. Jones DA, Weeraman D, Colicchia M, Hussain MA, Veerapen D, Andiapen M, et al. The impact of cell therapy on cardiovascular outcomes in patients with refractory angina. Circ Res 2019;124:1786–95. https://doi.org/10.1161/circresaha.118.314118 1204. Giannini F, Baldetti L, Konigstein M, Rosseel L, Ruparelia N, Gallone G, et al. Safety and efficacy of the reducer: a multi-center clinical registry—REDUCE study. Int J Cardiol 2018;269:40–4. https://doi.org/10.1016/j.ijcard.2018.06.116 1205. Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:1505–35. https://doi. org/10.1002/ejhf.1236 1206. Adamo M, Grasso C, Capodanno D, Rubbio AP, Scandura S, Giannini C, et al. Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: insights from the multicenter GRASP-IT registry. Am Heart J 2019;217:32–41. https://doi.org/10.1016/j.ahj.2019.06.015 1207. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126. https://doi.org/ 10.1093/eurheartj/ehac262 1208. Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention 2021;17:791–808. https://doi.org/ 10.4244/eij-d-21-00695 1209. Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. New Engl J Med 2023;388:1833–42. https://doi.org/10.1056/NEJMoa2300525 1210. Sogaard R, Diederichsen ACP, Rasmussen LM, Lambrechtsen J, Steffensen FH, Frost L, et al. Cost effectiveness of population screening vs. no screening for cardiovascular disease: the Danish Cardiovascular Screening trial (DANCAVAS). Eur Heart J 2022; 43:4392–402. https://doi.org/10.1093/eurheartj/ehac488 1211. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007;32:375–410. https://doi.org/10.1016/j.cpcardiol.2007.04.001

ESC Guidelines                                                                                                                                                                                          3537

Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026